Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

European Society for Medical Oncology

The leading professional organisation for medical oncology

Visit the ESMO Website

Guidelines

ESMO Gastric Cancer Living Guideline

To cite this living guideline, please include the original Clinical Practice Guideline citation "Ann Oncol 2022;33(10):1005-1020" and this online publication, including date and version number: "ESMO Gastric Cancer Living Guideline, v1.4 September 2024"

This living guideline was initially prepared by F Lordick, L Candia Montero, L Castelo-Branco, G Pentheroudakis, C Sessa and E Smyth, on behalf of the Clinical Practice Guideline author group.
v1.4 was prepared by F Lordick and E Smyth.

Version:
1.4 - September 2024

ESMO Metastatic Colorectal Cancer Living Guideline

To cite this living guideline, please include the original Clinical Practice Guideline citation "Ann Oncol 2023;34(1):10-32" and this online publication, including date and version number:"ESMO Metastatic Colorectal Cancer Living Guideline, v1.2 September 2024"

This living guideline was prepared by A Cervantes, L Castelo-Branco, L Candia Montero, C Sessa, G Pentheroudakis and E Martinelli, on behalf of the Clinical Practice Guideline author group.
v1.2 was prepared by A Cervantes, L Candia Montero, G Pentheroudakis and E Martinelli.
Updated treatment recommendations for third and further lines of treatment in advanced colorectal cancer: from the ESMO Metastatic Colorectal Cancer Living Guideline (Published online: 4 December 2024 - Annals of Oncology)

Version:
v1.2 - September 2024

ESMO Oncogene-Addicted Metastatic Non-Small-Cell Lung Cancer Living Guideline

To cite this living guideline, please include the original Clinical Practice Guideline citation "Ann Oncol. 2023;34(4):339-357" and this online publication, including date and version number: "ESMO Oncogene-Addicted Metastatic Non-Small-Cell Lung Cancer Living Guidelines, v1.1 July 2024

This living guideline was prepared by L Hendriks, F Cortiula, E Mariamidze, D Martins-Branco, G Pentheroudakis and M Reck, on behalf of the Clinical Practice Guideline author group.

Version:
v1.1 - July 2024

ESMO Non-Oncogene-Addicted Metastatic Non-Small-Cell Lung Cancer Living Guideline

To cite this living guideline, please include the original Clinical Practice Guideline citation "Ann Oncol. 2023;34(4):358-376" and this online publication, including date and version number: "ESMO Non-Oncogene-Addicted Metastatic Non-Small-Cell Lung Cancer Living Guidelines, v1.1 March 2024"

This living guideline was prepared by L Hendriks, F Cortiula, E Mariamidze, L Castelo-Branco, D Martins-Branco, C Sessa, G Pentheroudakis and M Reck, on behalf of the Clinical Practice Guideline author group.

Version:
v1.1 - March 2024

ESMO ​Metastatic Breast Cancer Living Guideline

To cite this living guideline, please include the original Clinical Practice Guideline citation "Ann Oncol 2021;32(12): 1475-1495" and this online publication, including date and version number: "ESMO Metastatic Breast Cancer Living Guidelines, v1.1 May 2023"

This living guideline was prepared by G Curigliano, L Castelo-Branco, A Gennari, N Harbeck, C Criscitiello and D Trapani, on behalf of the Clinical Practice Guideline author group.

Version:
v1.1 - May 2023

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.